The validity of this concept has first been demonstrated by the therapeutic efficacy of the BTK inhibitor ibrutinib in ABC DLBCL and other lymphoid cancers relying on chronic BCR signaling [67,89,253,254]. The gene discussed is BTK; the disease is aneurysmal bone cyst.